BNP Paribas Financial Markets Sells 43,254 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

BNP Paribas Financial Markets lessened its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 39.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 67,123 shares of the company’s stock after selling 43,254 shares during the quarter. BNP Paribas Financial Markets’ holdings in Autolus Therapeutics were worth $244,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AUTL. SG Americas Securities LLC lifted its stake in shares of Autolus Therapeutics by 853.2% in the 2nd quarter. SG Americas Securities LLC now owns 189,240 shares of the company’s stock worth $659,000 after purchasing an additional 169,387 shares during the period. Bank of New York Mellon Corp raised its position in Autolus Therapeutics by 74.5% in the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock worth $8,810,000 after acquiring an additional 1,080,897 shares during the period. Privium Fund Management B.V. boosted its stake in shares of Autolus Therapeutics by 220.9% during the 2nd quarter. Privium Fund Management B.V. now owns 160,639 shares of the company’s stock worth $543,000 after acquiring an additional 110,581 shares during the last quarter. Wealth Effects LLC grew its position in shares of Autolus Therapeutics by 19.5% during the 2nd quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock valued at $171,000 after acquiring an additional 8,000 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in shares of Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, December 5th. Finally, The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $2.58 on Tuesday. The stock has a fifty day simple moving average of $3.55 and a two-hundred day simple moving average of $3.83. The firm has a market capitalization of $686.51 million, a PE ratio of -2.13 and a beta of 1.98. Autolus Therapeutics plc has a 52-week low of $2.44 and a 52-week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the firm posted ($0.26) earnings per share. On average, sell-side analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.